Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 996 of 6351
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy. The study consists of two parts and a China …
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Could Lab-Grown eye cells restore sight in dry AMD?
Disease control Recruiting nowBackground: Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots. Researchers want to learn if replacing older eye cells with younger ones can help treat this disease. O…
Phase 1/2 • Sponsor: National Eye Institute (NEI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New combo therapy aims to slow advanced breast cancer
Disease control OngoingThis research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer. The names of the study interventions involved in this study are: * Sacituzumab govitecan (IMMU-132) * Pembrolizumab (Keyt…
Phase 2 • Sponsor: Ana C Garrido-Castro, MD • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Your genes may decide if metformin works for you
Knowledge-focused Recruiting nowThis prospective observational study will evaluate whether the SLC16A11 risk variant influences the response to metformin in adults with type 2 diabetes. Participants will be classified as carriers or noncarriers and followed for 6 months while receiving extended-release metformi…
Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Heart stent showdown: which device works best for blocked arteries?
Disease control OngoingMultivessel TALENT is a prospective, randomized, multi-center study comparing clinical outcomes between SUPRAFLEX Cruz and SYNERGY in approximately 1550 patients with de-novo three vessel disease undergoing percutaneous coronary intervention (PCI). Patients will be treated accord…
Sponsor: National University of Ireland, Galway, Ireland • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for advanced stomach cancer: drug combo aims to extend survival
Disease control Recruiting nowThis is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall sur…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for glioblastoma? early trial combines drug with radiation
Disease control OngoingThis phase I trial investigates the side effects and best dose of Peposertib, and to see how well it works in combination with radiation therapy in treating patients with newly diagnosed MGMT unmethylated glioblastoma or gliosarcoma. Radiation therapy uses high energy x-rays to k…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New urine test could spare bladder cancer patients from failed treatments
Diagnosis Recruiting nowTo date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diag…
Sponsor: Cedars-Sinai Medical Center • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
Experimental virus injection targets Hard-to-Treat cancers in new trial
Disease control Recruiting nowThis is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
Phase 1/2 • Sponsor: ImmVira Pharma Co. Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
AI camera could catch melanoma before It's too late
Diagnosis CompletedThe goal of this observational study is to learn if a computer-aided diagnosis (CAD) system can help identify skin cancer (cutaneous melanoma). The research focuses on adults who have skin spots that a doctor thinks might be cancerous. The main questions the study aims to answer …
Sponsor: AI Labs Group S.L • Aim: Diagnosis
Last updated Jun 27, 2026 11:02 UTC
-
MRI-Guided radiation boost shows promise in head and neck cancer trial
Disease control OngoingTo assess and localize hypoxic tumor subregions both at baseline and during the second week of radiotherapy. And to hypothesize that an intensified IMRT regimen may ensure higher local response rates compared to the standard IMRT approach.
Phase 2 • Sponsor: Regina Elena Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Can two radiation therapies team up to fight liver cancer?
Disease control OngoingThis study will investigate the combination of Ytrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT) followed by Stereotactic Body Radiation Therapy (SBRT). Y-90 SIRT alone or SBRT alone are standard procedures used in the treatment of liver cancer. This study will assess …
Phase 1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat cancers
Disease control OngoingThis is a Phase I, FIH, open-label, multi-site, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of claudin 6 (CLDN6) chimeric antigen receptor T cells (CAR-T) with or without CLDN6 ribonucleic acid lipoplexes (RNA-LPX) in patients with CLD…
Phase 1 • Sponsor: BioNTech Cell & Gene Therapies GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pfizer drug shows promise against tough cancers
Disease control OngoingTo assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ov…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New migraine shot shows promise for children in Long-Term study
Disease control CompletedThe primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to…
Phase 3 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug cocktail aims to keep childhood cancers at bay
Disease control Recruiting nowThe primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "s…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for dravet syndrome: phase 3 trial of EPX-100 aims to cut seizures
Disease control Recruiting nowThis is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).
Phase 3 • Sponsor: Epygenix • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Breast cancer breakthrough: thousands may avoid unnecessary surgery
Knowledge-focused OngoingNAUTILUS study is a prospective, multicenter, RCT. Clinically T1,T2, node negative BCS candidates with no evidence of metastases in AUS are 1:1 randomized into no SLNB group and SLNB group. NAUTILUS study aim to establish the minimally invasive treatment of breast cancer by reex…
Sponsor: Seoul National University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Virtual cues on a treadmill: a new hope for Parkinson's falls?
Disease control Stopped earlyGait disorder is a disabling symptom in Parkinson's disease (PD) affecting all patients during the course. Three methods of treadmill training (TT) will be compared to assess additional augmented reality (AR), or additional dual task (DT). AR TT, DT TT, and TT alone applied over …
Sponsor: Klinik Valens • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Proton therapy combo aims to shrink pancreatic tumors before surgery
Disease control Recruiting nowThis is an interventional, single arm, open-label, feasibility trial with gemcitabine and nab-paclitaxel, followed by concomitant proton therapy and capecitabine, followed by re-evaluation and surgery (when feasible) for patients with borderline resectable pancreatic cancer.
Sponsor: EBG MedAustron GmbH • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC